Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Centogene N.V. (CNTGF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: CNTGF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.62% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.26M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) - | Beta -0.12 | 52 Weeks Range 0.04 - 0.55 | Updated Date 06/16/2025 |
52 Weeks Range 0.04 - 0.55 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76368227 | Price to Sales(TTM) 0.09 |
Enterprise Value 76368227 | Price to Sales(TTM) 0.09 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 12252558 |
Shares Outstanding 29000100 | Shares Floating 12252558 | ||
Percent Insiders 4.57 | Percent Institutions 59.37 |
Upturn AI SWOT
Centogene N.V.
Company Overview
History and Background
Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany. It provides genetic testing and diagnostic services for rare diseases. The company went public in 2019.
Core Business Areas
- Genetic Diagnostics: Centogene provides genetic testing for a wide range of rare diseases, utilizing various technologies like next-generation sequencing (NGS) and Sanger sequencing.
- Pharma Partnerships: The company collaborates with pharmaceutical companies to support drug development programs by providing access to its rare disease data and diagnostic expertise.
- Bio/Data Bank: Centogene maintains a proprietary rare disease biobank and database, which is used for research, diagnostic, and therapeutic purposes.
Leadership and Structure
The leadership team consists of key executives overseeing various departments. The company is structured around its diagnostic services, pharma partnerships, and data assets.
Top Products and Market Share
Key Offerings
- CentoXomeu00ae: CentoXomeu00ae is Centogene's whole exome sequencing (WES) test. This product identifies the cause of rare diseases by sequencing protein coding genes in the human body. The market share is unavailable. Competing products include whole exome sequencing services offered by Invitae and similar companies.
- CentoGenomeu00ae: CentoGenomeu00ae is Centogene's whole genome sequencing (WGS) test. This product helps identify cause of rare diseases by sequencing the entire human genome, including non-coding regions and structural variations. The market share is unavailable. Competing products include whole genome sequencing services offered by Illumina and other sequencing providers.
- CentoPortalu00ae: The CentoPortalu00ae is a knowledge hub of rare disease insights. It is proprietary bio/data bank that can be licenced out and is exclusive to Centogene. The market share is unavailable.
Market Dynamics
Industry Overview
The genetic testing and diagnostics market is growing rapidly, driven by advancements in sequencing technologies and increasing awareness of rare diseases. The market includes clinical diagnostics, research and drug discovery.
Positioning
Centogene is positioned as a specialized provider of genetic testing and data analysis for rare diseases, focusing on pharma partnerships and proprietary biobank. Their focus on rare diseases is their competitive advantage.
Total Addressable Market (TAM)
The global genetic testing market is expected to reach hundreds of billions of USD. Centogene is positioned to address a significant portion of this TAM, particularly within the rare disease segment.
Upturn SWOT Analysis
Strengths
- Proprietary rare disease database
- Strong pharma partnerships
- Specialized expertise in rare disease diagnostics
- Global presence and network
Weaknesses
- High operating expenses
- Historically unprofitable
- Dependence on pharma collaborations
- Limited public awareness of the company
Opportunities
- Expansion of genetic testing services
- Growth in emerging markets
- Increasing adoption of precision medicine
- Development of new diagnostic technologies
Threats
- Competition from larger genetic testing companies
- Changes in regulatory landscape
- Price pressure in the genetic testing market
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- ILMN
- NVTA
- DGX
Competitive Landscape
Centogene faces competition from larger genetic testing companies with broader service offerings. Its competitive advantage lies in its specialized expertise in rare diseases and unique biobank.
Growth Trajectory and Initiatives
Historical Growth: Centogene's historical growth has been driven by increased demand for genetic testing and expansion of its pharma partnerships.
Future Projections: Future growth projections depend on market conditions, regulatory changes, and the company's ability to execute its strategic initiatives. Analyst estimates should be consulted for specific forecasts.
Recent Initiatives: Recent initiatives include expansion of diagnostic services, enhancement of its biobank, and strengthening pharma collaborations.
Summary
Centogene is a specialized genetic testing company focused on rare diseases, possessing a valuable biobank and pharma partnerships. The company faces challenges related to profitability and competition from larger players. Growth opportunities exist through expansion of services and increasing adoption of precision medicine. Centogene needs to manage expenses and solidify its market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 384 | Website https://www.centogene.com |
Full time employees 384 | Website https://www.centogene.com | ||
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.